Conditions

Home / Conditions

 

Fujirebio’s Diagnostic Test for Beta-amyloid Plaques Given FDA OK

Fujirebio’s Diagnostic Test for Beta-amyloid Plaques Given FDA OK

The U.S. Food and Drug Administration (FDA) has granted marketing permission to a new test that checks for amyloid plaques in people being checked for Alzheimer’s disease. The Lumipulse G β [beta]-Amyloid Ratio (1-42/1-40) test, which will be sold by Fujirebio Diagnostics, is now approved for adults ages 55 and up who are being evaluated…

Dosing Begins for Next Phase of Trial for Investigational Therapy AL001

Dosing Begins for Next Phase of Trial for Investigational Therapy AL001

Alzamend Neuro has dosed the first patient in the multiple ascending dose portion of its Phase 2a clinical trial of AL001, an investigational oral therapy for dementia related to Alzheimer’s disease. This multiple ascending dose (MAD) part follows positive results from a Phase 1 trial. Topline data from the Phase 2a trial is expected in…

Einstein Study Lands $32M NIH Grant to Study Aging Brain

Einstein Study Lands $32M NIH Grant to Study Aging Brain

The Einstein Aging Study has received a $32 million grant from the National Institutes of Health (NIH) to delve into the many risk factors that may determine cognitive decline and disease progression in people with Alzheimer’s. The study, ongoing at the Albert Einstein College of Medicine since 1980, focuses on the brain and how it…

CAR T-cell Therapy Safe, Effective in Treatment-resistant Myeloma: Study

CAR T-cell Therapy Safe, Effective in Treatment-resistant Myeloma: Study

A CAR T-cell therapy called CART-ddBCMA that targets the protein BCMA — produced at high levels in myeloma cells — safely led to lasting responses in relapsed and refractory multiple myeloma (RRMM) patients, a Phase 1 study showed. Given the small study size, further trials in larger groups of patients are needed to confirm these…

C2N Develops Blood Test to Measure Tau Forms in Alzheimer’s Research

C2N Develops Blood Test to Measure Tau Forms in Alzheimer’s Research

C2N Diagnostics has developed a new assay that precisely measures blood levels of four forms of tau, a protein involved in the brain changes observed in Alzheimer’s disease. Called the plasma tau multianalyte assay (p-tau MAA), the test is intended to be used for research purposes only and does not have current approval for use…

Activities Mark Alzheimer’s and Brain Awareness Month Across June

Activities Mark Alzheimer’s and Brain Awareness Month Across June

The start of summer holds the promise of beach trips, barbecues, and vacations, but for people with Alzheimer’s disease and their caregivers, family, and friends, June also means Alzheimer’s and Brain Awareness Month. Monthlong initiatives aim to honor the more than 55 million people living with dementia worldwide, according to Alzheimer’s Disease International. As it does…

New Community-driven Model Aims to Improve Alzheimer’s Screening

New Community-driven Model Aims to Improve Alzheimer’s Screening

An innovative new project in Toronto will combine optometry and community-based cognitive testing to improve Alzheimer’s screening and enable the early detection of the progressive neurodegenerative disorder. The project — launching in Ontario, Canada — will be led by the medical imaging company RetiSpec and the community-based medical center Toronto Memory Program. These collaborators are…

Tau-targeting Treatment Slows Cognitive, Functional Declines: Trial

Tau-targeting Treatment Slows Cognitive, Functional Declines: Trial

Alzheimer’s patients given the experimental tau-targeting therapy HMTM in a Phase 3 clinical trial experienced a substantially slower decline in cognitive and functional measures than would be expected based on published research, according to new findings announced by HMTM’s developer TauRx Pharmaceuticals. TauRx expects these results will support applications to gain  regulatory approvals of HMTM…

CYT-338 Shows Anticancer Activity in Preclinical Tests

CYT-338 Shows Anticancer Activity in Preclinical Tests

CYT-338, an investigational myeloma therapy designed to simultaneously bind to cancer cells and activate immune cells called natural killer cells, has shown promising anti-cancer activity in preclinical studies. A team led by scientists at Cytovia Therapeutics, the company developing CYT-338, will present the findings in a poster this month at the European Hematology Association’s 2022…

Brain Health Academy Will Offer Wellness Guidance to Professionals

Brain Health Academy Will Offer Wellness Guidance to Professionals

UsAgainstAlzheimer’s is preparing to launch free online courses – The Brain Health Academy – teaching health and wellness professionals how to help people reduce the risk of Alzheimer’s and dementia. Developed in partnership with the American Heart Association, The American College of Lifestyle Medicine, and the Centers for Disease Control and Prevention, the six-part course…

New VirtuALZ Program Aims to Offer Caregiver Support

New VirtuALZ Program Aims to Offer Caregiver Support

Caring for a loved one with Alzheimer’s disease (AD) can be overwhelming. To help ease the caregiver burden — and ultimately benefit patients — a Florida-based company called VirtuALZ is offering a new virtual support program. Crafted specifically to support caregivers of patients who have Alzheimer’s and related dementias, VirtuALZ’s program uses calls, texts, and…